Royalty Pharma Plc Cl A (RPRX)

$48.57 +0.08 (0.16%)
Market Cap 28.02B
Revenue (ttm) 2.38B
Net Income (ttm) 770.95M
EPS (ttm) N/A
PE Ratio 10.04
Forward PE 9.71
Profit Margin 32.42%
Debt to Equity Ratio 0.92
Volume 2,730,400
Avg Vol 3,633,644
Day's Range N/A - N/A
Shares Out 576.86M
Stochastic %K 88%
Beta 0.39
Analysts Strong Sell
Price Target $52.43

Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Industry: Biotechnology
Sector: Healthcare
Phone: 212 883 0200
Address:
110 East 59th Street, New York, United States
Night_Owl_Biotech
Night_Owl_Biotech Apr. 3 at 5:36 PM
The attachment notes the 22 commercial-stage bios trading within 10% of their highest closing share price since 12/1/2025 as of 4/2/2026. We count 89 such bios in total in this peer group (25 oncology focused with MCs over $300MM & 64 non-oncology focused with MCs over $800MM). $RPRX $KNSA $AGIO & $TGTX are the non-oncology bios in this peer group all trading at their highest share prices since 12/1/2025. $SNDX closed at its highest closing price in oncology. Thank you Goldman Sachs. SNDX investors may want to look at SNDX trading after Goldman's last upgrade that, our records reflect, was issued on 9/5/25. This is not investment advice.
1 · Reply
ajb_2010
ajb_2010 Apr. 2 at 3:26 PM
$XBI biotech ETF range bound but strong sector to hide out nice chart on $RPRX $SPY
0 · Reply
MorganHoratio
MorganHoratio Mar. 31 at 1:10 PM
$SYRE Big biotech read-through most are sleeping on: BTIG just reiterated Buy / $70 PT after $RPRX + $JNJ teamed up on JNJ-4804 (dual IL-23 + TNF approach). That’s not just noise — it validates the combo therapy thesis in IBD, exactly where $SYRE is positioning. Why it matters: Big Pharma doubling down on multi-pathway biology Direct sympathy to $SYRE’s SPY120/130/230 combo platform DUET data from $JNJ later this year = potential sentiment catalyst Pipeline timeline: 2Q26: SPY001 (anti-CD47) PoC readout 2026: SPY002 (TL1A) + SPY003 (IL-23) data follow 2027: Full Phase 2 combo data (SKYLINE) Underrated angle: TL1A is part of the TNF superfamily — historically validated pathways = higher probability setups. If TNF worked, TL1A could be next. More shots on goal: 3Q26: SPY072 (RA) 4Q26: axSpA + PsA data Translation: This isn’t a single binary biotech — it’s a platform bet with multiple catalysts lined up. Market hasn’t fully priced this in yet. Stay alert.
0 · Reply
Quantumup
Quantumup Mar. 31 at 11:41 AM
BTIG reiterated $SYRE Buy-$70 after $RPRX announced a co-funding agreement w/ $JNJ for the devt of JNJ-4804 (co-antibody of remfya+golimumab [IL-23+TNF]). Here's what BTIG had to say in its note: https://x.com/Quantumup1/status/2038944109151261006?s=20
0 · Reply
zerodayrounder
zerodayrounder Mar. 26 at 1:10 PM
so $TBPH sold its Trelegy royalty rights to $RPRX for $1.1 billion in 2022 (and retained "late-stage" royalties and milestones from Royalty Pharma if certain sales targets hit). In July 2025, TBPH sold its remaining "late stage" royalties to $GSK for $225 million. The Trelegy patent is supposed to end around 2031 and is a blockbuster for GSK. At one point, GSK owned 27% of TBPH but never purchased it outright -- although there was speculation it would 15 years ago. TBPH had multiple other drugs etc and wasn't basically just a one-drug royalty/shell company that has ceased new drug development like $SPRO ... Perhaps $GSK will take $SPRO in-house to avoid royalties like it did to clean up Trelegy royalty stream still retained by TBPH. https://gemini.google.com/share/4b89dc8a9570
1 · Reply
WAJeff
WAJeff Mar. 25 at 11:31 PM
Added $RPRX $47
0 · Reply
StockConsultant
StockConsultant Mar. 25 at 10:55 PM
$RPRX Royalty Pharma stock, nice rally off the 45.64 triple support area, breakout watch, from Stocks to Watch at https://stockconsultant.com/?RPRX
0 · Reply
TradeTracs
TradeTracs Mar. 23 at 7:49 PM
$RPRX another name found on our Trade Tracs Base Scanner, flagging above pivotal past resistance for a nice R/S flip. Inside day to start the week very constructive
0 · Reply
JuggernautRaider
JuggernautRaider Mar. 11 at 2:56 PM
$FBIO don’t be shocked if the sell the CUTX-101 royalty stream to $RPRX for a nice premium 🚀
1 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 11:34 PM
$RPRX Current Stock Price: $45.97 Contracts to trade: $45.0 RPRX Mar 20 2026 Call Entry: $1.20 Exit: $1.92 ROI: 60% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on RPRX
Royalty Pharma and J&J partner to develop autoimmune treatment

Mar 30, 2026, 9:14 AM EDT - 5 days ago

Royalty Pharma and J&J partner to develop autoimmune treatment

JNJ

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Mar 30, 2026, 7:15 AM EDT - 6 days ago

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

Mar 23, 2026, 7:15 AM EDT - 13 days ago

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

Royalty Pharma Announces Expansion of Leadership Team

Mar 17, 2026, 4:01 PM EDT - 18 days ago

Royalty Pharma Announces Expansion of Leadership Team

Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 3:52 PM EST - 4 weeks ago

Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

Mar 2, 2026, 7:00 AM EST - 4 weeks ago

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Mar 2, 2026, 6:10 AM EST - 4 weeks ago

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference

Feb 26, 2026, 4:15 PM EST - 5 weeks ago

Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference

Royalty Pharma: 2025 Financial Performance And Strategic Outlook

Feb 16, 2026, 3:39 AM EST - 6 weeks ago

Royalty Pharma: 2025 Financial Performance And Strategic Outlook

Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View

Feb 12, 2026, 12:16 PM EST - 7 weeks ago

Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View

Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript

Feb 11, 2026, 4:44 PM EST - 7 weeks ago

Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript

Royalty Pharma Reports Q4 and Full Year 2025 Results

Feb 11, 2026, 7:00 AM EST - 7 weeks ago

Royalty Pharma Reports Q4 and Full Year 2025 Results

Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Jan 20, 2026, 4:15 PM EST - 2 months ago

Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 3:05 PM EST - 2 months ago

Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

Jan 12, 2026, 12:26 PM EST - 2 months ago

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

TEVA

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:15 AM EST - 2 months ago

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Jan 11, 2026, 5:15 PM EST - 2 months ago

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma Announces Dividend Increase

Jan 9, 2026, 8:30 AM EST - 3 months ago

Royalty Pharma Announces Dividend Increase

Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones

Dec 29, 2025, 4:40 PM EST - 3 months ago

Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones

Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million

Dec 16, 2025, 7:15 AM EST - 3 months ago

Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Dec 4, 2025, 7:10 AM EST - 4 months ago

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Dec 4, 2025, 7:00 AM EST - 4 months ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

DNLI

Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 6:13 PM EST - 4 months ago

Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 5:33 PM EST - 4 months ago

Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Royalty Pharma to Present at Upcoming Investor Conferences

Nov 26, 2025, 8:15 AM EST - 4 months ago

Royalty Pharma to Present at Upcoming Investor Conferences

Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated

Nov 15, 2025, 7:12 AM EST - 5 months ago

Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated

Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 1:01 PM EST - 5 months ago

Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript

Royalty Pharma Reports Third Quarter 2025 Results

Nov 5, 2025, 7:00 AM EST - 5 months ago

Royalty Pharma Reports Third Quarter 2025 Results

Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences

Nov 4, 2025, 7:15 AM EST - 5 months ago

Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences

Royalty Pharma Declares Fourth Quarter 2025 Dividend

Oct 17, 2025, 8:15 AM EDT - 6 months ago

Royalty Pharma Declares Fourth Quarter 2025 Dividend

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

Oct 9, 2025, 4:15 PM EDT - 6 months ago

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

Sep 29, 2025, 8:15 AM EDT - 6 months ago

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

Royalty Pharma plc (RPRX) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Sep 23, 2025, 5:23 PM EDT - 6 months ago

Royalty Pharma plc (RPRX) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum

Sep 19, 2025, 4:25 PM EDT - 7 months ago

Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum

Royalty Pharma: Investor Day Upside

Sep 12, 2025, 3:54 PM EDT - 7 months ago

Royalty Pharma: Investor Day Upside

Royalty Pharma Plc (RPRX) Investor Day 2025 Call (Transcript)

Sep 11, 2025, 8:16 PM EDT - 7 months ago

Royalty Pharma Plc (RPRX) Investor Day 2025 Call (Transcript)

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation

Sep 11, 2025, 7:00 AM EDT - 7 months ago

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation

Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market

Sep 10, 2025, 7:30 AM EDT - 7 months ago

Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market

Royalty Pharma Plc (RPRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 6:07 PM EDT - 7 months ago

Royalty Pharma Plc (RPRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 4:15 PM EDT - 7 months ago

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

Sep 2, 2025, 8:30 PM EDT - 7 months ago

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

Sep 2, 2025, 7:15 AM EDT - 7 months ago

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

Sep 2, 2025, 7:05 AM EDT - 7 months ago

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

ZBIO

Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

Aug 25, 2025, 6:33 AM EDT - 7 months ago

Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

AMGN

Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million

Aug 25, 2025, 6:10 AM EDT - 7 months ago

Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

Aug 25, 2025, 6:00 AM EDT - 7 months ago

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

ONC

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

Aug 13, 2025, 4:15 PM EDT - 8 months ago

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

Royalty Pharma: Keep Delivering, Buy Confirmed

Aug 9, 2025, 6:23 AM EDT - 8 months ago

Royalty Pharma: Keep Delivering, Buy Confirmed

Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:52 PM EDT - 8 months ago

Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript

Royalty Pharma Reports Second Quarter 2025 Results

Aug 6, 2025, 7:00 AM EDT - 8 months ago

Royalty Pharma Reports Second Quarter 2025 Results

Night_Owl_Biotech
Night_Owl_Biotech Apr. 3 at 5:36 PM
The attachment notes the 22 commercial-stage bios trading within 10% of their highest closing share price since 12/1/2025 as of 4/2/2026. We count 89 such bios in total in this peer group (25 oncology focused with MCs over $300MM & 64 non-oncology focused with MCs over $800MM). $RPRX $KNSA $AGIO & $TGTX are the non-oncology bios in this peer group all trading at their highest share prices since 12/1/2025. $SNDX closed at its highest closing price in oncology. Thank you Goldman Sachs. SNDX investors may want to look at SNDX trading after Goldman's last upgrade that, our records reflect, was issued on 9/5/25. This is not investment advice.
1 · Reply
ajb_2010
ajb_2010 Apr. 2 at 3:26 PM
$XBI biotech ETF range bound but strong sector to hide out nice chart on $RPRX $SPY
0 · Reply
MorganHoratio
MorganHoratio Mar. 31 at 1:10 PM
$SYRE Big biotech read-through most are sleeping on: BTIG just reiterated Buy / $70 PT after $RPRX + $JNJ teamed up on JNJ-4804 (dual IL-23 + TNF approach). That’s not just noise — it validates the combo therapy thesis in IBD, exactly where $SYRE is positioning. Why it matters: Big Pharma doubling down on multi-pathway biology Direct sympathy to $SYRE’s SPY120/130/230 combo platform DUET data from $JNJ later this year = potential sentiment catalyst Pipeline timeline: 2Q26: SPY001 (anti-CD47) PoC readout 2026: SPY002 (TL1A) + SPY003 (IL-23) data follow 2027: Full Phase 2 combo data (SKYLINE) Underrated angle: TL1A is part of the TNF superfamily — historically validated pathways = higher probability setups. If TNF worked, TL1A could be next. More shots on goal: 3Q26: SPY072 (RA) 4Q26: axSpA + PsA data Translation: This isn’t a single binary biotech — it’s a platform bet with multiple catalysts lined up. Market hasn’t fully priced this in yet. Stay alert.
0 · Reply
Quantumup
Quantumup Mar. 31 at 11:41 AM
BTIG reiterated $SYRE Buy-$70 after $RPRX announced a co-funding agreement w/ $JNJ for the devt of JNJ-4804 (co-antibody of remfya+golimumab [IL-23+TNF]). Here's what BTIG had to say in its note: https://x.com/Quantumup1/status/2038944109151261006?s=20
0 · Reply
zerodayrounder
zerodayrounder Mar. 26 at 1:10 PM
so $TBPH sold its Trelegy royalty rights to $RPRX for $1.1 billion in 2022 (and retained "late-stage" royalties and milestones from Royalty Pharma if certain sales targets hit). In July 2025, TBPH sold its remaining "late stage" royalties to $GSK for $225 million. The Trelegy patent is supposed to end around 2031 and is a blockbuster for GSK. At one point, GSK owned 27% of TBPH but never purchased it outright -- although there was speculation it would 15 years ago. TBPH had multiple other drugs etc and wasn't basically just a one-drug royalty/shell company that has ceased new drug development like $SPRO ... Perhaps $GSK will take $SPRO in-house to avoid royalties like it did to clean up Trelegy royalty stream still retained by TBPH. https://gemini.google.com/share/4b89dc8a9570
1 · Reply
WAJeff
WAJeff Mar. 25 at 11:31 PM
Added $RPRX $47
0 · Reply
StockConsultant
StockConsultant Mar. 25 at 10:55 PM
$RPRX Royalty Pharma stock, nice rally off the 45.64 triple support area, breakout watch, from Stocks to Watch at https://stockconsultant.com/?RPRX
0 · Reply
TradeTracs
TradeTracs Mar. 23 at 7:49 PM
$RPRX another name found on our Trade Tracs Base Scanner, flagging above pivotal past resistance for a nice R/S flip. Inside day to start the week very constructive
0 · Reply
JuggernautRaider
JuggernautRaider Mar. 11 at 2:56 PM
$FBIO don’t be shocked if the sell the CUTX-101 royalty stream to $RPRX for a nice premium 🚀
1 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 11:34 PM
$RPRX Current Stock Price: $45.97 Contracts to trade: $45.0 RPRX Mar 20 2026 Call Entry: $1.20 Exit: $1.92 ROI: 60% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 8 at 4:29 PM
$RPRX Royalty Pharma Plc (NASDAQ: RPRX) is quietly becoming one of the most intriguing cheap biotech stocks as its royalty-based business model generates recurring revenue from blockbuster medicines. With analysts raising price targets and the company holding billions in financial firepower for new acquisitions, RPRX stock could offer investors exposure to biotech growth without the typical drug development risks. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-buy-royalty-pharma-rprx-shares/
0 · Reply
JuggernautRaider
JuggernautRaider Mar. 6 at 3:00 PM
$FBIO anyone else wondering if they’ll sell tbe CUTX-101 royalty stream to $RPRX ? 🧐
0 · Reply
TechridyStocks
TechridyStocks Mar. 6 at 1:39 AM
$RPRX still solid
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 2 at 1:39 PM
$RPRX (-7.2% pre) $ZYME (-3.3% pre) Ziihera cancer drug sparks $250M Royalty Pharma–Zymeworks deal https://ooc.bz/l/95120
0 · Reply
briefingcom
briefingcom Mar. 2 at 1:32 PM
$ZYME: Zymeworks & and Royalty Pharma $RPRX enter into $250 million royalty-backed note financing https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260302060706ZYME&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 2 at 12:15 PM
$RPRX Share Price: $46.22 Contract Selected: Oct 16, 2026 $52.5 Calls Buy Zone: $0.88 – $1.09 Target Zone: $1.55 – $1.90 Potential Upside: 67% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 28 at 2:05 AM
$SNDX SNDX did not record a "current portion of royalty financing agreement" on their 12/31/2025 Balance Sheet. The attachment summarizes the current & long-term obligations due RPRX as of the end of the last 5 quarters (per their Ks & Qs). The accounting for these royalty type agreements is complex. We are not CPAs but, generally speaking, the current portion represents amounts estimated due $RPRX over the following 12-months, allowing investors to determine SNDX calculated Niktimvo sales projections. SNDX, per their 10K, disclosed they increased the effective interest rate on this agreement by 4%. By itself, this suggests (or better said reconfirms) Niktimvo sales projections today are far higher than they were at the time they entered into the RPRX agreement in 11/2024. Be careful, we could be wrong (but doubt it). We have not listened to the call yet so perhaps the phenomenon was explained yesterday. If anyone can better explain please do so. $INCY $XBI $IBB
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 2:07 PM
$RPRX RSI: 83.57, MACD: 1.3636 Vol: 1.88, MA20: 43.08, MA50: 40.69 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
smartkarma
smartkarma Feb. 20 at 7:04 PM
$RPRX | Royalty Pharma’s Long Game—Synthetic Royalties, Portfolio Resilience, and Scalable Returns! "Royalty Pharma reported a strong set of results for the fourth quarter and full year 2025, reflecting continued momentum in portfolio receipts,..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/royalty-pharma-s-long-game-synthetic-royalties-portfolio-resilience-and-scalable-returns
0 · Reply
StockBraker
StockBraker Feb. 19 at 11:53 AM
$RPRX Mission accomplished
0 · Reply
d_risk
d_risk Feb. 11 at 11:35 PM
$RPRX - Royalty Pharma plc - 10K - Updated Risk Factors RPRX flags broader biopharma headwinds (trial failures, approvals, pricing, patents, safety) plus sharper leverage and liquidity constraints, higher concentration and competition for royalties, limited product visibility, expanded regulatory, IP, macro, and tax exposures, new key-person and organizational risks, and added legal, ESG, cybersecurity, and AI uncertainties. #PharmaceuticalRoyalties #OperationalRisk #MarketVolatility #FinancialLeverage #RegulatoryRisk #BiopharmaSector #ESGConcerns #IPChallenges #LiquidityConstraints #RegulatoryRisks 🟢 Added 🟠 Removed https://dev.d-risk.ai/RPRX/10-K/2026-02-11
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 11 at 12:44 PM
$RPRX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.38 down -19.15% YoY • Reported revenue of $622M up 4.78% YoY • Royalty Pharma expects full year 2026 Portfolio Receipts to be between $3.28B and $3.43B, reflecting an expected Royalty Receipts growth of 3% to 8%.
0 · Reply